1/7
07:00 am
ganx
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Medium
Report
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
1/6
07:00 am
ganx
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
High
Report
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
12/19
03:03 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
12/19
08:04 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/18
04:05 pm
ganx
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
High
Report
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
12/18
07:32 am
ganx
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]
High
Report
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]
12/18
07:00 am
ganx
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
High
Report
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
12/11
04:18 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/5
04:20 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:20 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/29
01:34 am
ganx
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]
Medium
Report
Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]
11/20
07:00 am
ganx
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Medium
Report
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
11/12
08:19 am
ganx
Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]
Medium
Report
Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]
11/12
07:00 am
ganx
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Medium
Report
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
11/7
04:17 am
ganx
Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients [Seeking Alpha]
Medium
Report
Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients [Seeking Alpha]
10/30
07:00 am
ganx
Gain Therapeutics to Present at Neuroscience 2025
Medium
Report
Gain Therapeutics to Present at Neuroscience 2025